On the road to eliminating long‐lived plasma cells—"are we there yet?".

Central to protective humoral immunity is the activation of B cells and their terminal differentiation into antibody‐secreting plasma cells. Long‐lived plasma cells (LLPC) may survive for years to decades. Such long‐lived plasma cells are also responsible for producing pathogenic antibodies that cause a variety of challenges such as autoimmunity, allograft rejection, and drug neutralization. Up to now, various therapeutic strategies aimed at durably eliminating pathogenic antibodies have failed, in large part due to their inability to efficiently target LLPCs. Several antibody‐based therapies have recently gained regulatory approval or are in clinical phases of development for the treatment of multiple myeloma, a malignancy of plasma cells. We discuss the exciting potential of using these emerging cancer immunotherapies to solve the antibody problem. [ABSTRACT FROM AUTHOR]